期刊文献+

HPLC法检查奥拉帕利原料中有关物质

HPLC determination of related substances in olaparib raw materials
原文传递
导出
摘要 目的:建立高效液相色谱法检测奥拉帕利原料中的有关物质。方法:采用YMC-Pack pro C_(18)AS(150 mm×4.6 mm,3μm)色谱柱,以0.05 mol·L^(-1)的磷酸二氢钾(用稀磷酸调pH至3.0)-甲醇-乙腈(90∶5∶5)为流动相A,甲醇-乙腈-水(45∶45∶10)为流动相B,进行梯度洗脱,流速0.8 mL·min^(-1),柱温30℃,检测波长210 nm,进样量10μL。结果:空白溶剂不干扰供试品溶液有关物质测定,系统适用性溶液中已知杂质Ⅰ~Ⅶ及未知杂质在该色谱系统中分离完好;奥拉帕利质量浓度在0.033~411.623μg·mL^(-1),杂质Ⅰ~Ⅶ质量浓度均在0.05~3.0μg·mL^(-1)与其峰面积呈较好的线性关系,其r均在0.999以上;杂质Ⅰ~Ⅶ平均回收率均大于92.0%(RSD均小于4.0%)。结论:HPLC法检查奥拉帕利原料有关物质方法专属性强,灵敏度高,准确度高,精密度好,可满足奥拉帕利原料有关物质检测需求。 Objective:To establish an HPLC method for the determination of related substances in olaparib raw materials.Methods:By using YMC-Pack pro C18 AS(150 mm×4.6 mm,3μm)column,0.05 mol·L^(-1) potassium dihydrogen phosphate(pH 3.0 adjusted with dilute phosphoric acid)-methanol-acetonitrile(90∶5∶5)was as mobile phase A and methanol-acetonitrile-water(45∶45∶10)was as mobile phase B,in gradient elution,with flow rate of 0.8 mL·min^(-1).The column temperature was 30℃,the detection wavelength was 210 nm,and the injection volume was 10μL.Results:The solvent blank did not interfere with the determination of relevant substances in the test solution,the known impuritiesⅠ-Ⅶand unknown impurities in the system suitability solution were well separated in the chromatographic system.Olaparib had a good linear relationship with its peak area in the concentration range of 0.083-333.133μg·mL^(-1).The concentrations of impuritiesⅠ-Ⅶwere 0.05-3.0μg·mL^(-1),there were good linear relationships with their peak area,and their r were 0.9997 or above.The average recoveries of impuritiesⅠ-Ⅶwere all above 92.0%,and RSDs were less than 4.0%.Conclusion:The HPLC method for the detection of the related substances of olaparib raw materials has strong specificity,high sensitivity,high accuracy and good precision,which can meet the requirements for the detection of related substances of olaparib raw materials.
作者 邹艳 吴海龙 邓丽 胡川 李宏名 ZOU Yan;WU Hai-long;DENG Li;HU Chuan;LI Hong-ming(Sinopharm Chuankang Pharmaceutical Co.,Ltd.,Chengdu 611731,China;Chengdu Kanghong Pharmaceutical Group Co.,Ltd.,Chengdu 610000,China)
出处 《药物分析杂志》 CAS CSCD 北大核心 2024年第8期1379-1386,共8页 Chinese Journal of Pharmaceutical Analysis
关键词 奥拉帕利 聚腺苷二磷酸核糖聚合酶(PARP)抑制剂 有关物质 方法研究 质量控制 高效液相色谱 olaparib PARP inhibitor related substances method study quality control high performance liquid chromatography(HPLC)
  • 相关文献

参考文献10

二级参考文献49

  • 1SIEGELR, MA J, ZOU Z, et al. Cancer statistics[J]. CA Cancer J Clin, 2014,64( 1 ) :9 - 29.
  • 2AstraZeneca AB. Lynparza 50 mg hard capsules: EU summary ofproduct characteristics[ EB/OL], 2014. http ://www. ema. euro- pa. eu/ema.
  • 3AstraZeneca Pharmaceuticals LP. LynparzaTM (olaparib) cap- sules, for oral use : US prescribing information ~ EB/OL ]. 2014. http ://www. accessdata, fda. gov/scripts/cder/drugsatfda/index. cfm.
  • 4BRYANT HE, SCHULTZ N, THOMAS HD, et al. Specific kill- ing BRCA2-deficient tumours with inhibitors of poly ( ADP-ri- bose) polymerase [ J ]. Nature, 2005, 434 ( 7035 ) : 913 - 917.
  • 5BURGESS M, PUHALLA S. BRCA l/2-mutation retated and sporadic breast and ovarian cancers: more alike than different [J]. Front Oncol, 2014, 4:19.
  • 6EMMA DD. Olararib: First global approval[ J]. Drugs, 2015, 75(2) :231 -240.
  • 7LEDERMANN J, HARTER P, GOURLEY C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer [J]. NEnglJMed, 2012, 366(15):1382-1392.
  • 8MATULONIS UA, HARTER P, GOURLEY C, et al. Analysis of intermediate clinical endpoints from a phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) [ abstract no. 132 ~ I J]. Gyne- col Oneo1,2014,133 ( Suppl 1 ) : $54 - $55.
  • 9LEDERMANN J, HARTER P, GOURLEY C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer : a preplanned retrospective analysis of out- comesby BRCA status in a randomized phase 2 trial~ J]. Lancet Oncol, 2014,15(8) :852 -861.
  • 10KAYE SB, LUBINSKI J, MATULONIS U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibi- tor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer [ J]. J Clin Oncol,2011,30(4) :372 -379.

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部